Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04511052
Other study ID # A12-M57-19B
Secondary ID IT15250
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date November 1, 2021
Est. completion date September 13, 2022

Study information

Verified date November 2023
Source McGill University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Carotenoids are yellow-orange fat soluble plant pigments primarily obtained from the diet that serve as an accurate biomarker for fruit and vegetable intake. Carotenoids have demonstrated antioxidant, anti-inflammatory, and anti-obesogenic properties among others. Excess carotenoids are deposited in the skin for storage where they protect against UV skin damage and contribute to improvements in skin health (i.e., decrease the appearance of wrinkles). However, carotenoid status is linked to bioavailability and absorption, which has a high inter-individual variability. It has been hypothesized that inter-individual variations are related to the diversity of gut microbiota. The aim of the present study is to determine whether probiotic supplementation can enhance carotenoid status and responsiveness to carotenoid-mediated changes in blood and skin from intake of a supplement containing mixed forms of carotenoids in pre-menopausal women.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date September 13, 2022
Est. primary completion date September 13, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 30 Years to 50 Years
Eligibility Inclusion Criteria: 1. Healthy non-menopausal or non-perimenopausal women, 2. 30-50 years of age, 3. BMI of 18.5 - 29.9 kg/m2, 4. Access to a smartphone that has a camera and iOS 11.0 or Android 4.2 and up, 5. Visible fine to moderate wrinkles on the face (e.g. forehead, crow's feet area, etc.), 6. Fitzpatrick scale of types I, II, & III 7. Urine pregnancy test of negative 8. Willing to maintain current physical activity and dietary habits 9. Willing to refrain from taking natural health products containing carotenoids (beta-carotene, lutein, lycopene, etc.) 10. Willing to discontinue consumption of probiotic supplements and food containing added probiotics (e.g. yogurts with live, active cultures or supplements) or fermented foods (e.g. Kefir, pickles, etc.) upon screening and for the duration of the study, 11. Willing to apply the moisturizer provided on every day throughout the study upon admission to the study (about -2 weeks), 12. Willing to refrain from using any cream (including the moisturizer provided) and makeup on the face for study visits and photo capture (face, eyes and lips), 13. Able to understand and comply with requirements of the study (e.g. complete all clinical visits, questionnaires, records, and diaries), 14. Able to provide a written informed consent. Exclusion Criteria: 1. Known immunodeficiency (immuno-compromised and immuno-suppressed participant; e.g. AIDS, lymphoma, participants undergoing long-term corticosteroid treatment, chemotherapy and allograft participant), 2. Known chronic or acute illness (e.g. hepatitis, diabetes, high blood pressure, jaundice, etc.), unless under control via medication, 3. History of illness or use of any type of drug that may interfere with the investigational product or intervention (e.g. antibiotics) within 1 month of screening (may be eligible to participate after a 2-week washout period), 4. Known chronic or acute skin condition on the face (e.g. eczema, psoriasis, severe acne, rosacea, etc.), 5. Facial surgery (e.g. lifting, facial rejuvenation) or chemical treatment (e.g. Botox injection) within 5 years before study start, 6. Frequent tanning salons, use tanning products, or foresee high exposure to the sun during the study, 7. Tattoos on the face or palms of the hands, 8. Milk, soy or yeast allergy, 9. Routine use of dietary supplements that may interfere with outcomes measured (e.g. anti-oxidant, anti-inflammatory, herbal), 10. Use of probiotic products in the past 2 weeks (may be eligible to participate after a 2-week washout period), 11. Allergy to any of the ingredients contained in the moisturizer provided, 12. Use of antiaging creams containing retinol, glycolic acid, Coenzyme Q, etc. (may be eligible to participate after a 2 weeks washout period upon admission to the study), 13. Current smoker (tobacco or cannabis), 14. Excessive alcohol consumption (>1 drink/day), 15. Drug abuse or addiction, 16. Bleeding/blood disorder 17. Psychological disorder 18. Currently enrolled in another trial 19. Positive pregnancy test in women of child-bearing potential; breast-feeding or planning on becoming pregnant during the course of the study (determined by a pregnancy test performed at the screening visit), 20. Women of child-bearing potential not using effective contraception which include: - Hormonal contraceptives including combined oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormonal implants - Intrauterine devices (IUD) or Intrauterine system (IUS) - Tubal ligation - Vasectomy of partner - Barrier method (condom or occlusive cap with spermicide) - Abstinence 21. Participation in a similar study within 3 months of the screening visit.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotic
Daily intake of 10 x 10^9 CFU of a proprietary strain for a total duration of 10 weeks
Other:
Placebo
1 capsule daily containing the same carrier material that is similar in size, shape and taste to the probiotic, for a duration of 10 weeks
Dietary Supplement:
Carotenoid supplement
1 capsule daily containing ~20 mg of total carotenoids for a total duration of 10 weeks

Locations

Country Name City State
Canada Mary Emily Clinical Nutrition Research Unit (7 rue maple) Sainte-Anne-de-Bellevue Quebec

Sponsors (2)

Lead Sponsor Collaborator
McGill University Lallemand Health Solutions

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in skin yellow color saturation measured by a spectrophotometer Average b* value (yellow coloration designated by the CIELab color space) measured from the palm and forehead by spectrophotometry Week 0, 5, and 10
Secondary Changes in blood plasma carotenoid status Blood plasma HPLC or LC-MS analysis Week 0, 5, and 10
Secondary Changes in yellow skin color saturation measured by image analysis Average b* value (yellow coloration designated by the CIELab color space) measured by image analysis of the palm and forehead Week 0, 5, and 10
Secondary Changes in fecal microbial composition 16s rRNA sequencing Week -2, 0, 5, and 10
Secondary Changes in recovery of probiotic strain 16s rRNA qPCR Week -2, 0, 5, and 10
Secondary Changes in skin hydration Measured using a Courage + Khazaka probe system Week 0, 5, and 10
Secondary Changes in skin elasticity Measured using the Tewameter probe from Courage + Khazaka probe system Week 0, 5, and 10
Secondary Changes in skin trans-epidermal water loss Measured using a Courage + Khazaka probe system Week 0, 5, and 10
Secondary Changes in facial skin wrinkling Images of participants will be individually rated by two trained specialists based on the skin aging atlas 1 - Caucasian type book at four different regions: forehead, crow's feet, nasolabial fold, and upper lip Week 0, 5, and 10
Secondary Changes in plasma interleukin 1ß (IL-1ß) levels Assessed with MILLIPLEX MAP Human High Sensitivity T Cell Panel - Immunology Multiplex Assay. Week 0, 5, and 10
Secondary Changes in plasma interleukin-6 (IL-6) levels Assessed with MILLIPLEX MAP Human High Sensitivity T Cell Panel - Immunology Multiplex Assay. Week 0, 5, and 10
Secondary Changes in plasma interleukin-8 (IL-8) levels Assessed with MILLIPLEX MAP Human High Sensitivity T Cell Panel - Immunology Multiplex Assay Week 0, 5, and 10
Secondary Changes in plasma tumor necrosis factor- a (TNF-a) levels Assessed with MILLIPLEX MAP Human High Sensitivity T Cell Panel - Immunology Multiplex Assay. Week 0, 5, and 10
Secondary Changes in plasma 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels Assessed via LC-MS Week 0, 5, and 10
Secondary Changes in plasma F-2 isoprostane levels Assessed via LC-MS Week 0, 5, and 10
Secondary Changes in plasma progesterone levels Analysis using MILLIPLEX MAP Multi-Species Hormone Magnetic Bead Panel Week 0, 5, and 10
Secondary Changes in plasma estradiol levels Analysis using MILLIPLEX MAP Multi-Species Hormone Magnetic Bead Panel Week 0, 5, and 10
Secondary Changes in plasma testosterone levels Analysis using MILLIPLEX MAP Multi-Species Hormone Magnetic Bead Panel Week 0, 5, and 10
Secondary Changes in plasma cortisol levels Analysis using MILLIPLEX MAP Multi-Species Hormone Magnetic Bead Panel Week 0, 5, and 10
Secondary Changes in plasma cholesterol levels Using a colorimetric assay Week 0, 5, and 10
Secondary Changes in plasma antioxidant capacity Measured using the 2,2'-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid (ABTS) assay Week 0, 5, and 10
Secondary Changes in Vitamin A status Plasma HPLC analysis Week 0, 5, and 10
Secondary Changes in perceived health and attractiveness A perception trial is a validated method used to determine the attractiveness preferences of participants (Lefevre & Perrett, 2015). Images of participants from the intervention trial will be sent to the Department of Psychology at McGill University, where the laboratory coordinator will set up an electronic survey that will display randomized sets of images from the same intervention participant at all timepoints (week 0, 5, and 10) of the intervention, in randomized order of presentation (left and right). A separate group of 60 participants will be recruited to participate in the perception trial and assess the images of the intervention participants. These participants will be trained using a few sample photos and then will be instructed to choose the most attractive and healthy looking face in a forced-choice paradigm for each comparison presented in the electronic survey. Week 0, 5, and 10
Secondary Changes in quality of life assessed by SF-36 questionnaire The short form 36-Item Health Survey 1.0 Questionnaire is a validated questionnaire that will be used to assess QoL as a recent study (Valler-Colomer et al., 2019) demonstrated a consistent association between higher QoL indicators and particular gut microbiota profiles (butyrate-producing Faecalibacterium and Coprococcus bacteria). This survey consists of 36 items that average together to indicate eight scale scores for various health indicators (e.g., emotional well-being, general health, etc.). Scores range from 0-100, with higher scores representing better health. Carotenoid supplementation has also demonstrated improvements in sub-optimal symptoms of physical and emotional health measured via various self-reported questionnaires (Stringham et al., 2018). Week 0, 5, and 10
See also
  Status Clinical Trial Phase
Recruiting NCT05793112 - INF108F in Infants With Food Protein Induced Proctocolitis Phase 4
Active, not recruiting NCT04327141 - Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women N/A
Recruiting NCT04117321 - Mother-infant Microbiota Transmission and Its Link to the Health of the Baby
Recruiting NCT05655910 - Enhanced Nutritional Optimization in LVAD Trial N/A
Recruiting NCT03325855 - Fecal Microbiota Transplant National Registry
Active, not recruiting NCT05931471 - Yogurt and GI Health N/A
Recruiting NCT03797417 - Gut Microbiome and Metabolic Pathways Changes in Vitiligo
Withdrawn NCT06006416 - Effect of Fenugreek Fibre on Gut Microbiome Phase 3
Recruiting NCT06206486 - The Gut Microbiome and Serum Metabolites as a Biological Mechanism Underlying Pain in Kidney Transplantation
Completed NCT02655250 - Neonatal Microbiome Validity Study
Recruiting NCT05670288 - Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord Injury
Not yet recruiting NCT03975764 - Fecal Microbiota in Preterm Birth
Completed NCT03219931 - NEOBIFI: Clinical Trial for the Prevention and/or Reduction of the Incidence of Colics in Infants Phase 4
Recruiting NCT04466072 - Gut Microbiome and Ventricular Arrhythmias
Recruiting NCT04447365 - The Correlation Between Gut Microbiome-host Interaction and Ventricular Arrhythmias.
Not yet recruiting NCT06130137 - Gut Microbiome in People Living With HIV and HBV
Recruiting NCT06260579 - Home-based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity N/A
Active, not recruiting NCT06424691 - Infant Restore: Efficacy of Microbiome Analysis and Education N/A
Recruiting NCT06404749 - Fungal Fiber for Gut Health N/A
Not yet recruiting NCT06433310 - Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study Early Phase 1